The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 20 of the 36 sources its claims cite were checked for support.
Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors
Open accessAbstract
Significance: The ribosome is a large and complex RNA–protein complex that synthesizes proteins in all kingdoms of life. The sequences of bacterial ribosomes differ, and antibiotics exploit these differences to inhibit the ribosome and stop cell growth. Mutations in the ribosome can interfere with antibiotic binding and render the bacteria resistant to the antibiotic. Using a combination of structural, biophysical, and biochemical experiments, we show how rRNA mutations alter the structure of the ribosome at the antibiotic binding site and result in divergent antibiotic susceptibility profiles.
Overview
CoChat Summary
TL;DR
Negamycin-resistant 16S rRNA mutations U1052G and U1060A both reduce negamycin susceptibility, but U1052G unexpectedly becomes hypersusceptible to tetracycline while remaining non-hypersusceptible to tigecycline. Structural and single-molecule experiments link this divergent profile to h34 distortion and a previously unidentified second tetracycline binding site in the U1052G mutant ribosome.
Key findings
- U1052G and U1060A confer negamycin resistance: MIC values were 256 and 128 µg/mL versus 32 µg/mL for wild-type, with in vitro translation IC50 values of 13 and 11 µM versus 2.9 µM for wild-type.
- U1052G is hypersusceptible to tetracycline: MIC 0.5 µg/mL versus 2 µg/mL for wild-type, and in vitro translation IC50 2.7 µM versus 15 µM for wild-type; U1060A was tetracycline-resistant (MIC 16 µg/mL; IC50 51 µM).
- X-ray crystallography showed U1052G disrupts the U1052–G1206 wobble pair and displaces the G1053 phosphate by ∼2 Å, while also revealing a second tetracycline molecule bound ∼20 Å from the established site near the 16S central pseudoknot and ribosomal protein S5; no second site was found in wild-type or U1060A ribosomes.
- U1052G showed no hypersusceptibility to tigecycline (MIC 2 µg/mL; IC50 0.36 µM versus wild-type MIC 2 µg/mL and IC50 0.28 µM), and modeling suggested the tigecycline butylglycylamido substituent would clash with S5 at the novel site.
Methods
- The study used microbiological MIC measurements, luminescence-based in vitro-coupled transcription–translation assays with purified components, X-ray crystallography of E. coli strain SQ171 70S ribosomes, and single-molecule FRET (smFRET) to monitor aa-tRNA selection.
- Ribosomes were wild-type or carrying U1052G or U1060A mutations; antibiotic complexes included negamycin, tetracycline, and tigecycline, with structures deposited under PDB IDs 5IT8, 5J5B, 5J91, 5JC9, 5J7L, 5J8A, and 5J88.
- Crystallographic data were processed with XDS/SCALA/autoPROC, solved by molecular replacement with MOLREP, rebuilt in Coot, and refined with autoBUSTER; smFRET experiments tracked Cy3-labeled initiator tRNA and LD650-labeled Phe-tRNAPhe in ternary complex with EF-Tu and GTP.
Limitations
- The paper states that attempts to introduce G966U or G1058C tetracycline-resistance mutations together with U1052G failed to produce viable clones, and a randomized library at positions 965–967 yielded tetracycline-resistant isolates only with wild-type U1052, preventing direct mutagenic testing of the novel binding site’s function.
- The paper states that future work is needed to determine whether other antibiotic resistance mutations in pathogens create novel antibiotic binding sites that can be exploited therapeutically.
- Evident from the text: the causal role of the second tetracycline binding site in U1052G hypersusceptibility is supported by correlation with structural and smFRET data, but the attempted functional disruption of that site was not achieved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 3 Not valid · 11 Not checked · 54 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The mechanism of action for both antibiotics is to interfere with tRNA binding to the aminoacyltRNA (aa-tRNA) site of the small 30S ribosomal subunit (11, 12).”
What the sources say
- Disputedcites [11] sourceExperimental — accuracy not yet measured
The paper directly contradicts the claim for negamycin: the Abstract and Introduction state that although the NEG site overlaps that of tetracycline, 'while TET sterically hinders binding of aminoacyl-tRNA to the ribosome, NEG stabilizes its binding thereby inhibiting translocation and stimulating miscoding', and the section 'NEG and TET: same site, different modes of action' (RESULTS AND DISCUSSION) adds that NEG 'likely increases the affinity of the tRNA to the ribosomal A site, while TET and its derivatives compete with aminoacyl-tRNA binding'. Only the tetracycline half of the claim is supported (and there the paper credits Blanchard et al. 2004, Brodersen et al. 2000, Jenner et al. 2013); the two antibiotics are described as having opposite, not shared, mechanisms. The 30S/h34 location is consistent for NEG, but the paper also reports binding to both subunits at 9 sites. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Disputedcites [12] sourceExperimental — accuracy not yet measured
Our copy states the opposite of the claim for negamycin: the Abstract reports that 'in contrast to tetracycline-class antibiotics, which serve to prevent cognate tRNA from entering the translating ribosome,' negamycin 'specifically stabilizes near-cognate ternary complexes within the A site... to promote miscoding.' The results section ('Negamycin Displaces Tetracycline from the Ribosome but Is Not') adds that at 200 μM negamycin 'the mechanism of cognate aa-tRNA selection was unaffected' and 'negamycin's interactions with the ribosome do not sterically impinge on the entry of cognate aa-tRNA as it enters the A site,' whereas tetracycline/tigecycline block the CR-to-GA transition. So only the tetracycline half of the claim matches; the shared 'interference with tRNA binding to the aa-tRNA site' mechanism the citation is offered for is directly contradicted, with the paper's point being that negamycin binds an overlapping h34/head-domain site but alters decoding fidelity rather than blocking tRNA binding. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The phosphate group of A1197 also engages negamycin through a bound Mg 2 + ion.”
What the sources say
- Disputedcites [11] sourceExperimental — accuracy not yet measured
Our copy assigns the Mg2+-mediated phosphate contact to a different residue: in the h34 backbone section (RESULTS, 'NEG binding to the site of its action requires proper configuration of the 16S rRNA backbone') it states that 'The terminal carboxylic moiety of NEG forms a magnesium-mediated contact with the phosphate group of nucleotide 1052,' and the only other hydrated-magnesium bridge described (RESULTS, 'NEG interacts with the A-site tRNA') links the drug's terminal carboxyl to the 3'-phosphate of tRNA nucleotide 34. For residue 1197 the paper describes direct contacts instead — hydrogen bonds with the backbone of nucleotides 965, 966, 1054 and 1197, and, in 'NEG may induce miscoding by stabilizing aminoacyl-tRNA binding in the A site', placement 'fixed by the interaction between its positively charged β-amino group and the 5'-phosphate of G1197'. Thus the source contradicts the claim that residue 1197's phosphate engages negamycin via a bound Mg2+ ion. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The crystallography section ('Crystal Structure of E. coli 70S Ribosome in Complex with Negamycin') does describe negamycin contacting the phosphate of A1197, but assigns that contact to the C4 amino group extending toward the A1197 phosphate backbone, while the bound Mg2+ ion is engaged by the C6 carbonyl group. The only Mg2+-to-phosphate statement is generic ('the presence of two Mg2+ ions within the binding site ... serves to increase the number of interactions with the phosphate backbone of the ribosome'), so the specific claim that A1197's phosphate engages negamycin through a bound Mg2+ is not stated by our copy. Our copy also hedges the whole binding pose as 'the most plausible model' because unambiguous placement was not possible at ~3.1 A resolution, whereas the citing sentence states it as fact. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Negamycin ' s impact on miscoding is, however, significantly suppressed by the U1052G resistance mutation (12).”
What the sources say
- Supportedcites [12] source
The Results section (p. of 'Negamycin Displaces Tetracycline from the Ribosome but Is Not...') states verbatim that 'negamycin's impact on the tRNA selection process was significantly suppressed by the U1052G resistance mutation (Fig. 3 A and B)', and Fig. 3B is explicitly the miscoding readout (fraction of near-cognate UCU-programmed ribosomes completing selection). Passage [5] ties the same figure to increased miscoding frequency, and passage [4] documents the U1052G resistance mutation conferring an ~30-fold MIC increase. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The negamycin-bound structure of the wild-type 70S E. coli ribosome shows that the phosphate oxygen of nucleotide G1053 is within 4.3 Å of the methyl group on N8 of negamycin (12).”
What the sources say
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
Our copy does report a negamycin-bound E. coli 70S crystal structure (~3.1 Å, classical-state ribosome) and enumerates its binding-mode contacts (Crystal Structure of E. coli 70S Ribosome in Complex with Negamycin): difference density next to the phosphate backbone of C1054, A1197 and G1198 near h34, with the carboxylate near the 2'-hydroxyl of A1196 and a phosphate oxygen of C1054, C6 carbonyl to a Mg2+, C4 amino toward A1197's phosphate backbone and C2 hydroxyl toward G966. However, no passage names nucleotide G1053, an 'N8' methyl group, or any 4.3 Å atom-atom distance, so the specific quantitative contact the citing sentence attributes is not stated. The copy also explicitly hedges the model: unambiguous placement of negamycin into the electron density map was not possible at the present resolution and a variety of binding modes were considered, and negamycin's methylated nitrogen is described as the 1-methylhydrazino group of [2-[(3R,5R)-3,6-diamino-5-hydroxyhexanoyl]-1-methylhydrazino]acetic acid rather than N8. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The MIC value of tetracycline for the U1052G mutant was fourfold lower than that of the wild-type ribosome (12) (Table 1).”
What the sources say
- Supportedcites [12] source
Table 1 of our copy (Materials and Methods) lists tetracycline (TET) MICs of 2 μg/mL for the wild-type strain and 0.5 μg/mL for its U1052G derivative in the SQ171 pHK-rrnC background — an exactly fourfold reduction — and the Results state that 'the U1052G mutation resulted in hypersusceptibility to tetracycline (Table 1)'. One caveat on scope: in the other background tabulated, SQ110 rrnE, the U1052G TET MIC is 0.12 vs 2 μg/mL (~16-fold), and the MICs are measured in whole cells (strains ATCC25922/SQ110/SQ171) rather than on isolated ribosomes, so 'wild-type ribosome' is loose wording for the wild-type strain. The magnitude attributed (fourfold) is nonetheless present in this source's data. (LLM, conf=0.82)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
41 more claims · 5 with their cited sources checked
Create a free account to see all 77 claims and to verify the 16 references still open.
- It may state two separate claims as one. 22
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Structural studies identified the mRNA decoding center in the 30S ribosomal subunit as the primary binding site, wherein tetracyclines bind close to the acceptor site (A site) codon and compete with the incoming A-site tRNA7–10.”
From Dual site targeting of the bacterial 70S ribosome by tetracyclines (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The crystal structure of U1060A E. coli 70S ribosome (PDB: 5J88) revealed that this mutation causes A1197 to unstack and protrude towards the mRNA channel9.”
From Dual site targeting of the bacterial 70S ribosome by tetracyclines (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The binding of all three tetracyclines at the canonical binding site of C. acnes and E. coli 70S ribosome was consistent with previously reported structural studies7–10,12.”
From Dual site targeting of the bacterial 70S ribosome by tetracyclines (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Results and Discussion · p. 4
“( D ) Superposition of the tetracycline-bound crystal structures of the wild-type and U1052G mutant ribosome. The dotted arrow represents the displacement of the phosphate group of nucleotide G1053 in the U1052G mutant. ( E ) This panel is rotated 90° along the vertical axis.”
§ Results and Discussion · p. 5
“The crystal structures of tigecycline bound to the wild-type ribosome and the U1052G mutant revealed that the butylglycylamido substituent is stacked against nucleotide C1054 in its established binding site (Fig. 4 C and E ).”
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Molecular replacement with MOLREP
Vagin, A., & Teplyakov, A. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042589 · Cited by 3,604
Data processing and analysis with the autoPROC toolbox
Vonrhein, C., Flensburg, C., Keller, P., Sharff, A., Smart, O., Paciorek, W., Womack, T., & Bricogne, G. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911007773 · Cited by 2,029
Carter, A. P., Clemons, W. M., Brodersen, D. E., Morgan-Warren, R. J., Wimberly, B. T., & Ramakrishnan, V. (2000) · Nature · doi:10.1038/35030019 · Cited by 1,615
Structures of the Bacterial Ribosome at 3.5 Å Resolution
Schuwirth, B. S., Borovinskaya, M. A., Hau, C. W., Zhang, W., Vila-Sanjurjo, A., Holton, J. M., & Cate, J. H. D. (2005) · Science · doi:10.1126/science.1117230 · Cited by 1,418
Self-citationRibosome-targeting antibiotics and mechanisms of bacterial resistance
Wilson, D. N. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3155 · Cited by 1,054
Smart, O. S., Womack, T. O., Flensburg, C., Keller, P., Paciorek, W., Sharff, A., Vonrhein, C., & Bricogne, G. (2012) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911056058 · Cited by 612
Research works printed but not linked: 2
- G Bricogne, Buster Version V2.11.6 (Global Phasing Ltd., Cambridge, UK, 2011).
- OS Smart, Grade V. 1.2.9 (Global Phasing Ltd., Cambridge, UK, 2011).
Cited by
Tetracycline-Inactivating Enzymes
Markley, J. L., & Wencewicz, T. A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01058 · Cited by 188
Odilorhabdins, Antibacterial Agents that Cause Miscoding by Binding at a New Ribosomal Site
Pantel, L., Florin, T., Dobosz-Bartoszek, M., Racine, E., Sarciaux, M., Serri, M., Houard, J., Campagne, J., de Figueiredo, R. M., Midrier, C., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.001 · Cited by 156
Endogenous rRNA Sequence Variation Can Regulate Stress Response Gene Expression and Phenotype
Kurylo, C. M., Parks, M. M., Juette, M. F., Zinshteyn, B., Altman, R. B., Thibado, J. K., Vincent, C. T., & Blanchard, S. C. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.093 · Cited by 117
Self-citationMarinus, T., Fessler, A. B., Ogle, C. A., & Incarnato, D. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1255 · Cited by 98
Structural conservation of antibiotic interaction with ribosomes
Paternoga, H., Crowe-McAuliffe, C., Bock, L. V., Koller, T. O., Morici, M., Beckert, B., Myasnikov, A. G., Grubmüller, H., Nováček, J., & Wilson, D. N. (2023) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01047-y · Cited by 94
Metadata
- Authors
- Cocozaki, A. I., Altman, R. B., Huang, J., Buurman, E. T., Kazmirski, S. L., Doig, P., Prince, D. B., Blanchard, S. C., Cate, J. H. D., & Ferguson, A. D.
- Affiliations
- AstraZeneca (United States) (US)
- Tri-Institutional PhD Program in Chemical Biology (US)
- University of California, Berkeley (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-07-05
- Volume
- 113
- Issue
- 29
- Pages
- 8188-8193
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4961145
- OpenAlex
- W2462749337
- Cited by
- 56
- References
- 37
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 3 · 2021: 4 · 2020: 9 · 2019: 2 · 2018: 9 · 2017: 1
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
- Funders
- AstraZeneca
- National Institute of General Medical Sciences (R01GM079238, R01GM098859)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- antibiotic resistance, translation inhibitors, negamycin, tetracycline, 16S rRNA, 30S ribosomal subunit, tRNA binding, ribosome structure, Escherichia coli
- MeSH terms
- Amino Acids, Diamino, Anti-Bacterial Agents, Escherichia coli, Mutation, Protein Synthesis Inhibitors, Ribosomes, RNA, Bacterial, RNA, Ribosomal, Tetracycline, Drug Resistance, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors. https://app.cochat.ai/papers/10.1073/pnas.1605127113
- The paper
- Cocozaki, A. I., Altman, R. B., Huang, J., Buurman, E. T., Kazmirski, S. L., Doig, P., Prince, D. B., Blanchard, S. C., Cate, J. H. D., & Ferguson, A. D. (2016). Resistance mutations generate divergent antibiotic susceptibility profiles against translation inhibitors. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1605127113
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.